17.07.03 · mol-cell-bio / signaling

PI3K-Akt-mTOR pathway: growth factor response, nutrient sensing, and cancer connections

stub3 tiersLean: nonepending prereqs

Anchor (Master): Saxton, R. A. & Sabatini, D. M. — Cell 168 (2017) 960-976

Intuition Beginner

Cells need to know when to grow. A growth factor molecule landing on the cell surface is the external signal, but the cell needs internal machinery to translate that signal into actual growth — building more proteins, lipids, and organelles. The PI3K-Akt-mTOR pathway is that machinery.

The pathway works in three stages. First, a lipid kinase called PI3K modifies a membrane lipid, converting PIP2 into PIP3. This creates a docking site on the inner surface of the membrane. Second, a protein kinase called Akt binds to PIP3 and gets activated by two phosphorylation events. Akt is the workhorse — it phosphorylates many downstream targets that promote cell survival and growth. Third, a master regulator called mTOR integrates the growth-factor signal with information about nutrient availability and energy status.

When this pathway is mutated, cells can grow uncontrollably. PIK3CA (the gene encoding the catalytic subunit of PI3K) is one of the most frequently mutated oncogenes in human cancer. PTEN, the brake on this pathway, is one of the most frequently lost tumor suppressors.

Visual Beginner

Picture a chain that starts at the cell surface and ends at the ribosome, the cell's protein-building factory. A growth factor binds its receptor, activating PI3K at the membrane. PI3K converts the membrane lipid PIP2 into PIP3, like flipping a chemical switch on the inner surface of the membrane. Akt and its activator PDK1 sense PIP3 and move to the membrane, where PDK1 phosphorylates Akt. A second kinase, mTORC2, adds a second phosphate. Fully active Akt then relays the signal to mTORC1 through the TSC1/TSC2 complex.

mTORC1 is the output hub. When active, it phosphorylates S6K (accelerating ribosome production) and inactivates 4E-BP1 (unlocking translation initiation). The cell ramps up protein synthesis and cell growth.

Worked example Beginner

Consider a breast cancer cell with a PIK3CA mutation that makes PI3K constitutively active. Trace the consequences.

Step 1. PI3K is always on, so PIP3 is constantly being produced in the membrane, even without growth factor.

Step 2. Akt is recruited to the membrane and phosphorylated by PDK1 and mTORC2 at all times.

Step 3. Active Akt phosphorylates FOXO transcription factors, keeping them out of the nucleus. FOXO target genes that promote cell death are silenced.

Step 4. Akt inhibits the TSC1/TSC2 complex. Without TSC1/TSC2 acting as a brake, the small GTPase Rheb stays GTP-loaded and activates mTORC1.

Step 5. mTORC1 drives protein synthesis through S6K and 4E-BP1. The cell grows and divides without the normal requirement for external growth-factor signals.

The cancer cell has bypassed the growth-factor checkpoint. Drugs targeting PI3K (alpelisib) or mTOR (everolimus) aim to restore the brake.

Check your understanding Beginner

Exercise (easy, multiple choice).

What is the function of PTEN in the PI3K-Akt-mTOR pathway?

A. It phosphorylates Akt B. It converts PIP3 back to PIP2, acting as a brake on the pathway C. It activates mTORC1 directly D. It produces PIP3 from PIP2

Hint

PTEN is a phosphatase — it removes phosphate groups. Think about which direction would oppose PI3K activity.

Answer

B. It converts PIP3 back to PIP2, acting as a brake on the pathway. PTEN (phosphatase and tensin homolog) is a lipid phosphatase that dephosphorylates the 3-position of PIP3, reversing the reaction catalyzed by PI3K. By keeping PIP3 levels low, PTEN restrains Akt activation. Loss of PTEN function — by mutation, deletion, or epigenetic silencing — is found in a large fraction of human cancers and leads to constitutive Akt signaling.

Exercise (easy, multiple choice).

mTORC1 integrates which of the following signals?

A. Growth factor signals only B. Nutrient availability only C. Growth factor signals, nutrient availability, and energy status D. DNA damage signals

Hint

The "m" in mTOR stands for "mechanistic," but the pathway's biological role is as an integrator of multiple inputs that determine whether the cell should grow.

Answer

C. Growth factor signals, nutrient availability, and energy status. mTORC1 requires inputs from growth-factor signaling (via Akt and TSC1/TSC2), amino acid availability (via Rag GTPases that recruit mTORC1 to the lysosomal surface), and cellular energy (via AMPK, which inhibits mTORC1 when ATP is low). This multi-input integration ensures that the cell commits resources to growth only when all conditions are favorable.

Exercise (medium, numeric).

In a cell with wild-type PI3K and PTEN, the steady-state ratio of PIP3 to PIP2 is approximately 1:100. If a PIK3CA hotspot mutation doubles PI3K activity and PTEN is heterozygously lost (reducing PTEN protein by half), estimate the new PIP3/PIP2 ratio. Assume steady state where PIP3 production rate equals PIP3 removal rate.

Hint

At steady state, production = removal. If PI3K doubles and PTEN halves, both changes push PIP3 up.

Answer

At steady state: $k_{PI3K} \cdot [PIP2] = k_{PTEN} \cdot [PIP3]$ . So $[PIP3] / [PIP2] = k_{PI3K} / k_{PTEN}$ .

Originally the ratio is $1/100$ . Doubling PI3K activity gives $2/100$ . Halving PTEN activity further doubles the ratio: $2/50 = 1/25$ .

The new steady-state ratio is approximately 1:25, a 4-fold increase in PIP3 relative to PIP2. This substantially increases Akt recruitment and activation, modeling the combined effect of PIK3CA mutation and PTEN haploinsufficiency seen in many tumors.

Formal definition Intermediate+

The PI3K-Akt-mTOR pathway is a signal transduction cascade that couples growth-factor receptor activation to the control of cell growth, survival, metabolism, and autophagy through a lipid-second-messenger module (PI3K/PIP3) feeding into a protein-kinase module (Akt/PKB) that regulates the mechanistic target of rapamycin complexes (mTORC1 and mTORC2).

PI3K class IA: structure and activation

Class IA PI3Ks are heterodimers of a regulatory subunit (p85, encoded by PIK3R1/R2/R3) and a catalytic subunit (p110, encoded by PIK3CA, PIK3CB, or PIK3CD). The p85 subunit contains SH2 domains that bind phospho-tyrosine motifs on activated RTKs or on adapter proteins (such as IRS1 downstream of the insulin receptor). This binding relieves an inhibitory interaction between p85 and p110, activating the lipid kinase. Additionally, Ras-GTP can bind the Ras-binding domain of p110, providing a second activation route that couples PI3K to the MAPK pathway described in 17.07.02.

The enzymatic reaction catalyzed by PI3K is phosphorylation of the 3-hydroxyl of the inositol ring of phosphatidylinositol-4,5-bisphosphate (PIP2) to generate phosphatidylinositol-3,4,5-trisphosphate (PIP3):

PI(4,5)P_{2} + ATP PI3K PI(3,4,5)P_{3} + ADP .

PIP3 constitutes a small fraction of the total membrane phosphoinositide pool (the basal PIP3/PIP2 ratio is approximately 0.01), but its local concentration at sites of receptor activation can increase 10- to 100-fold within seconds.

PTEN: the PIP3 phosphatase

PTEN (phosphatase and tensin homolog deleted on chromosome 10) is the primary brake on PI3K signaling. PTEN is a lipid phosphatase that dephosphorylates the 3-phosphate of PIP3, regenerating PIP2. PTEN also has protein-phosphatase activity, but its tumor-suppressor function is primarily attributed to lipid dephosphorylation. PTEN is frequently inactivated in cancer by mutation, deletion, promoter methylation, or post-translational modification. The result is elevated PIP3 and constitutive Akt activation.

Akt/PKB: the central kinase

Akt (also called PKB, protein kinase B) is a serine/threonine kinase with three isoforms (Akt1/PKB-alpha, Akt2/PKB-beta, Akt3/PKB-gamma). Akt contains a pleckstrin-homology (PH) domain that binds PIP3 and PI(3,4)P2 with high affinity. PIP3 binding recruits Akt to the plasma membrane and induces a conformational change that exposes two regulatory phosphorylation sites:

Thr308 in the activation loop, phosphorylated by PDK1 (3-phosphoinositide-dependent protein kinase 1), which is also PIP3-recruited.
Ser473 in the hydrophobic motif, phosphorylated by mTORC2.

Dual phosphorylation produces full Akt activity. Phosphorylation at Thr308 alone gives partial activity (approximately 10-20% of maximal); phosphorylation at both sites is required for full activation.

Akt substrates

Active Akt phosphorylates numerous substrates controlling growth, survival, and metabolism:

TSC2 (tuberin): Akt phosphorylates TSC2 on multiple sites, inhibiting the TSC1/TSC2 GAP complex. TSC1/TSC2 acts as a GTPase-activating protein for Rheb, keeping Rheb GDP-loaded and inactive. When TSC2 is phosphorylated by Akt, the GAP activity drops, Rheb accumulates in the GTP-bound state, and Rheb-GTP activates mTORC1.
FOXO transcription factors (FOXO1, FOXO3a, FOXO4): Akt phosphorylation creates binding sites for 14-3-3 proteins, which sequester FOXOs in the cytoplasm. This inhibits transcription of pro-apoptotic genes (BIM, PUMA, FASL) and cell-cycle inhibitors (p27, p21).
GSK3-beta: Akt phosphorylates the autoinhibitory Ser9 of GSK3-beta, inhibiting its kinase activity. GSK3-beta inhibition stabilizes beta-catenin (promoting Wnt signaling), increases glycogen synthase activity (promoting glycogen storage), and affects cyclin D1 stability.
BAD: Akt phosphorylation of BAD at Ser136 creates a 14-3-3 binding site, sequestering BAD away from the anti-apoptotic proteins Bcl-2 and Bcl-xL, promoting cell survival.

mTOR complexes

The mechanistic target of rapamycin (mTOR) is a serine/threonine kinase in the PI3K-related kinase (PIKK) family. It assembles into two distinct complexes:

mTORC1 contains mTOR, Raptor (regulatory-associated protein of mTOR), mLST8, PRAS40, and DEPTOR. mTORC1 is rapamycin-sensitive. It is activated by Rheb-GTP at the lysosomal surface and integrates:

Growth factor signals via Akt-TSC2-Rheb.
Amino acid signals via Rag GTPases (RagA/B in complex with RagC/D), which recruit mTORC1 to the lysosomal surface where Rheb resides. The Ragulator complex and the v-ATPase on the lysosomal membrane are essential for amino-acid sensing.
Energy signals via AMPK, which phosphorylates TSC2 (activating it) and Raptor (inhibiting mTORC1 directly) when the AMP/ATP ratio is high.

mTORC1 downstream targets include:

S6K (p70 ribosomal protein S6 kinase): Phosphorylates ribosomal protein S6 and other translation regulators, promoting ribosome biogenesis and translation elongation.
4E-BP1 (eIF4E-binding protein 1): In its hypophosphorylated state, 4E-BP1 binds and inhibits eIF4E, the cap-binding protein required for translation initiation. mTORC1 phosphorylation of 4E-BP1 causes its dissociation from eIF4E, unlocking cap-dependent translation.
ULK1 (UNC-51-like kinase 1): mTORC1 phosphorylates ULK1 on Ser757, inhibiting autophagy initiation. Under nutrient deprivation, mTORC1 is inactive, ULK1 is dephosphorylated, and autophagy proceeds.

mTORC2 contains mTOR, Rictor (rapamycin-insensitive companion of mTOR), mLST8, mSIN1, Protor, and DEPTOR. mTORC2 is insensitive to acute rapamycin treatment (though prolonged rapamycin can inhibit mTORC2 assembly in some cell types). mTORC2 phosphorylates Akt at Ser473, and also phosphorylates SGK1 and PKC-alpha, controlling cytoskeletal organization, ion transport, and cell survival.

Kinetic framework

The PI3K-Akt-mTOR pathway can be modeled as a cascade of enzyme-catalyzed reactions. At the PI3K step:

\frac{d [ PIP _{3} ]}{d t} = k_{PI3K} [RTK^{*}] [PIP_{2}] - k_{PTEN} [PTEN] [PIP_{3}] .

At steady state, $[PIP_{3}] / [PIP_{2}] = k_{PI3K} [RTK^{*}] / k_{PTEN} [PTEN]$ , providing a linear dependence of PIP3 on the ratio of PI3K to PTEN activity. Akt activation follows a Hill-type response to PIP3 concentration, reflecting cooperative recruitment of both Akt and PDK1 to the membrane. The pathway's dose-response from growth-factor input to mTORC1 output is steep, with effective cooperativity arising from the multi-step amplification and the switch-like nature of TSC2 phosphorylation.

Key mechanism Intermediate+

Mechanism (TSC-Rheb-mTORC1 activation switch). The TSC1/TSC2 complex acts as a GTPase-activating protein (GAP) for Rheb, converting Rheb-GTP to Rheb-GDP. Rheb-GTP is the direct activator of mTORC1. Akt-mediated phosphorylation of TSC2 inhibits the GAP activity, allowing Rheb-GTP to accumulate and activate mTORC1. The switch is sharpened by the multi-site phosphorylation of TSC2: Akt phosphorylates TSC2 on at least five sites (S939, S981, T1130, S1132, S1462 in human TSC2), and the combined effect on GAP inhibition is supralinear.

The multi-site phosphorylation of TSC2 produces an ultrasensitive response. If each phosphorylation event contributes independently to GAP inhibition, the fraction of fully inhibited TSC2 depends on a high power of Akt activity. For $n$ phosphorylation sites with independent, equal contribution:

f_{inhibited} \approx (\frac{[ Akt ^{*} ] ^{n}}{K ^{n} + [ Akt ^{*} ] ^{n}}),

with effective Hill coefficient near $n$ . This is the same distributive-phosphorylation ultrasensitivity discussed in 17.07.02 for the MAPK cascade, applied here to the TSC2 node. Experimental measurements of the Akt-TSC2-mTORC1 step report effective Hill coefficients of 2-4, consistent with contributions from multiple phosphorylation sites and from the cooperative nature of TSC2 dimerization.

The lysosomal recruitment step provides an additional layer of coincidence detection. mTORC1 must simultaneously bind Rag-GTP (anchoring it to the lysosomal surface) and Rheb-GTP (activating its kinase domain). This AND-gate logic ensures that mTORC1 is fully active only when both amino acids (Rag signal) and growth factors (Rheb signal) are present.

Exercises Intermediate+

Exercise 1 (easy, symbolic).

State the role of each of the following proteins in the PI3K-Akt-mTOR pathway: PI3K, PTEN, PDK1, Akt, TSC1/TSC2, Rheb, mTORC1.

Hint

PI3K is a lipid kinase, PTEN is a lipid phosphatase, PDK1 phosphorylates Akt, TSC1/TSC2 is a GAP for Rheb, and Rheb activates mTORC1.

Answer

PI3K: Lipid kinase that phosphorylates PIP2 to generate PIP3 at the plasma membrane, creating docking sites for PH-domain proteins including Akt and PDK1. Activated by RTK phospho-tyrosines (via p85 SH2 domains) or by Ras-GTP.

PTEN: Lipid phosphatase that dephosphorylates PIP3 back to PIP2, opposing PI3K and acting as the pathway brake. Major tumor suppressor.

PDK1: 3-phosphoinositide-dependent protein kinase 1. Constitutively active but requires PIP3 recruitment to the membrane for access to Akt. Phosphorylates Akt on Thr308.

Akt/PKB: Serine/threonine kinase activated by PIP3 recruitment plus dual phosphorylation (Thr308 by PDK1, Ser473 by mTORC2). Phosphorylates downstream targets controlling growth (TSC2), survival (FOXO, BAD), and metabolism (GSK3-beta).

TSC1/TSC2: Heterodimeric GAP complex that converts Rheb-GTP to Rheb-GDP. Acts as the integration node between Akt signaling and mTORC1 activation. Phosphorylation by Akt inhibits its GAP activity.

Rheb: Small GTPase that directly binds and activates mTORC1 when GTP-loaded. Substrate of the TSC1/TSC2 GAP. Constitutively localized to the lysosomal membrane via farnesylation.

mTORC1: Serine/threonine kinase complex containing mTOR and Raptor. Activated by Rheb-GTP and Rag GTPases. Controls protein synthesis (via S6K and 4E-BP1), ribosome biogenesis, lipid synthesis, and autophagy.

Exercise 2 (easy, symbolic).

Explain why loss of PTEN leads to increased cell growth and survival, and name two cancer types where PTEN loss is common.

Hint

PTEN removes PIP3. Without PTEN, what happens to Akt? What does active Akt do to FOXO and BAD?

Answer

PTEN loss leads to PIP3 accumulation because the PI3K reaction (PIP2 to PIP3) proceeds unchecked. Elevated PIP3 recruits Akt and PDK1 to the membrane, leading to constitutive Akt activation. Active Akt then:

Phosphorylates FOXO transcription factors, sequestering them in the cytoplasm and silencing pro-apoptotic genes (BIM, PUMA).
Phosphorylates BAD, preventing it from inhibiting Bcl-2/Bcl-xL, promoting survival.
Phosphorylates TSC2, inhibiting the TSC1/TSC2 GAP, activating Rheb and mTORC1, driving growth.

PTEN loss is found in glioblastoma (approximately 30-40% of cases), endometrial carcinoma, prostate cancer, melanoma, and many other tumor types. PTEN haploinsufficiency (loss of one allele) is sufficient to promote tumorigenesis in mouse models, and even subtle reductions in PTEN expression can shift the signaling balance toward growth.

Exercise 3 (medium, symbolic).

The amino acid leucine activates mTORC1 through the Rag GTPase pathway. Describe the sequence of events from leucine availability to mTORC1 activation at the lysosomal surface, and explain why this mechanism ensures mTORC1 is only active when growth factors and amino acids are simultaneously present.

Hint

Rag GTPases recruit mTORC1 to the lysosomal surface. Rheb is also on the lysosomal surface. mTORC1 needs both Rag and Rheb to be active.

Answer

The leucine-sensing pathway to mTORC1 proceeds as follows:

Leucine (and other amino acids) are detected by sensors on the lysosomal surface. The Sestrin2 protein is a leucine sensor that, when leucine-free, inhibits the GATOR2 complex. Leucine binding to Sestrin2 releases this inhibition. CASTOR1 performs an analogous role for arginine.
GATOR2 activates the RagA/B GEF (Ragulator), which promotes GTP loading of RagA/B. Simultaneously, GATOR1 (a GAP for RagA/B) is inhibited. The active Rag heterodimer is RagA/B-GTP / RagC/D-GDP.
Active Rag heterodimers bind Raptor on mTORC1, recruiting mTORC1 from the cytoplasm to the lysosomal surface.
At the lysosomal surface, mTORC1 encounters Rheb-GTP (which is constitutively farnesylated and lysosome-anchored). Rheb-GTP allosterically activates the mTOR kinase domain.
Full mTORC1 activation requires both inputs: Rag-mediated lysosomal recruitment AND Rheb-GTP binding. This is a coincidence detector (AND gate): amino acids provide the Rag signal (spatial recruitment), and growth factors provide the Rheb signal (kinase activation). Neither alone is sufficient for full activation.

This design ensures the cell does not waste resources synthesizing proteins when growth factors signal division but nutrients are scarce, or when nutrients are available but there is no division signal.

Exercise 4 (medium, numeric).

A PI3K inhibitor reduces PIP3 production by 80% (leaving 20% of baseline activity). PTEN loss in the same cell increases PIP3 levels by 5-fold relative to wild-type cells with normal PI3K. Estimate the net change in PIP3 levels in a PTEN-null cell treated with this PI3K inhibitor, compared to a wild-type cell with no inhibitor.

Hint

Combine the two effects multiplicatively. A 5-fold increase from PTEN loss times 0.20 from the inhibitor.

Answer

Let the wild-type PIP3 level be $[PIP3]_{0}$ . PTEN loss gives $5 \times [PIP3]_{0}$ . The PI3K inhibitor reduces production to 20% of baseline. Since PTEN is absent, the only removal route for PIP3 is other phosphatases or dilution, but the steady state is set by production rate. The new steady-state PIP3 is approximately $5 \times 0.20 \times [PIP3]_{0} = 1.0 \times [PIP3]_{0}$ .

The two effects roughly cancel: PTEN loss increases PIP3 5-fold, but 80% PI3K inhibition reduces it 5-fold. This illustrates a pharmacological principle — PI3K inhibitors may need to achieve near-complete inhibition in PTEN-null tumors to suppress PIP3 below the wild-type level, because even 20% PI3K activity produces enough PIP3 to sustain Akt signaling when PTEN is absent. This is one reason why PI3K inhibitors show limited efficacy as single agents in PTEN-deficient cancers.

Exercise 5 (hard, symbolic).

Active S6K phosphorylates IRS1 on inhibitory serine residues, targeting IRS1 for degradation and reducing its ability to propagate the insulin/IGF-1 signal. Draw the feedback loop and determine its sign (positive or negative). Explain why this feedback loop creates resistance to mTOR inhibitors in tumors with upstream PI3K or RTK mutations.

Hint

If mTORC1 is inhibited, S6K activity drops. What happens to IRS1? What does freed IRS1 do to PI3K? Does this help or hinder the drug?

Answer

The feedback loop is negative:

RTK $\to$ IRS1 $\to$ PI3K $\to$ PIP3 $\to$ Akt $\to$ TSC2(inh) $\to$ Rheb(act) $\to$ mTORC1 $\to$ S6K $\to$ IRS1(inh, degradation)

When mTORC1 is active, S6K phosphorylates IRS1 on serine residues (S302, S307, S636/639 in human IRS1), causing IRS1 degradation and reducing upstream signaling. This is a negative feedback loop that limits pathway output under normal conditions.

When an mTOR inhibitor (e.g., everolimus) blocks mTORC1, S6K is inactivated. IRS1 is no longer phosphorylated on inhibitory serines. IRS1 protein levels recover, and IRS1 propagates the insulin/IGF-1 signal more effectively to PI3K. This increases PIP3 production and Akt activation upstream of the drug's target.

In tumors with PIK3CA mutations or RTK amplifications, the relieved feedback produces a strong rebound in Akt phosphorylation (measured as increased p-Akt S473) despite ongoing mTORC1 inhibition. The upstream signal is amplified through the now-unbraked IRS1-PI3K axis. This feedback relief is a major mechanism of resistance to rapalogs and explains why mTORC1 inhibitors alone often produce cytostatic rather than cytotoxic responses.

The pharmacological solution is combination therapy: dual PI3K/mTOR inhibitors (e.g., dactolisib/BEZ235) that block both the upstream (PI3K) and downstream (mTOR) nodes simultaneously, preventing the feedback-driven Akt reactivation.

Exercise 6 (hard, symbolic).

Compare the signaling logic of the MAPK cascade (Ras-Raf-MEK-ERK from 17.07.02) with the PI3K-Akt-mTOR pathway. Address: (a) the chemical nature of the signal carrier at the first step, (b) the amplification mechanism, (c) the integration of multiple inputs, and (d) which pathway is more frequently mutated in cancer and why.

Hint

The MAPK cascade is a protein-kinase cascade throughout. PI3K-Akt-mTOR starts with a lipid modification. Think about what makes each pathway's signal integration different.

Answer

(a) Signal carrier at first step. The MAPK cascade uses protein phosphorylation at every step — Ras activation is followed by Raf, MEK, and ERK phosphorylation events. The PI3K-Akt-mTOR pathway begins with a lipid modification: PI3K converts the membrane lipid PIP2 to PIP3, creating a diffusible membrane-localized second messenger that recruits PH-domain proteins. The PI3K pathway thus resembles the GPCR second-messenger architecture (from 17.07.01) more than the serial kinase relay of the MAPK cascade.

(b) Amplification mechanism. The MAPK cascade amplifies through stacked kinase tiers — each kinase phosphorylates many substrates, producing multiplicative gain. The PI3K pathway amplifies at the PIP3 step (one active PI3K produces many PIP3 molecules) and at the Akt step (one active Akt phosphorylates many substrates), but the cascade is shorter — two major tiers rather than three. The PI3K pathway compensates by having a broader substrate spectrum: Akt directly phosphorylates over 100 known substrates.

(c) Integration of multiple inputs. The MAPK cascade primarily integrates growth-factor signals (although it receives crosstalk from GPCRs via PKC). The PI3K-Akt-mTOR pathway is a richer signal integrator: mTORC1 specifically requires simultaneous growth-factor input (via Akt-TSC2-Rheb) AND amino-acid input (via Rag GTPases) AND sufficient energy (via AMPK). This makes the PI3K-Akt-mTOR pathway the cell's master growth controller, while the MAPK cascade is primarily a proliferation/differentiation switch.

(d) Mutation frequency in cancer. The PI3K-Akt-mTOR pathway is arguably the most mutated pathway in human cancer. PIK3CA mutations occur in approximately 30-40% of breast cancers, 20-30% of endometrial cancers, and significant fractions of colorectal and other cancers. PTEN loss is found in glioblastoma, endometrial, prostate, and many other cancers. The combined frequency of PI3K-pathway alterations (PIK3CA mutation, PTEN loss, Akt amplification, PIK3R1 mutation) exceeds 50% across all solid tumors. The MAPK pathway (KRAS, BRAF, NRAS, EGFR mutations) is also highly mutated but at a lower overall frequency (approximately 30% of all cancers). The PI3K pathway's higher mutation burden may reflect its central role in integrating growth signals with nutrient availability — a function that, when dysregulated, gives cancer cells a growth advantage across diverse metabolic environments.

Exercise 7 (hard, symbolic).

Rapamycin extends lifespan in mice by approximately 15-25%, even when treatment begins late in life. Propose a molecular mechanism connecting mTORC1 inhibition to lifespan extension, citing at least three downstream effects of mTORC1 that are relevant to aging.

Hint

mTORC1 controls autophagy, protein synthesis, inflammation, and stem cell function. Which of these decline with age, and how would mTORC1 inhibition help?

Answer

The mTORC1-lifespan connection operates through several mechanisms:

Autophagy induction. mTORC1 phosphorylates and inhibits ULK1, the kinase that initiates autophagy. Rapamycin-mediated mTORC1 inhibition de-represses ULK1, restoring autophagy. Autophagy clears damaged organelles (mitochondria via mitophagy), aggregated proteins, and intracellular debris that accumulate with age. Reduced autophagy is a hallmark of aging tissues, and its restoration by rapamycin is considered the primary longevity mechanism.
Reduced protein synthesis and proteostasis. mTORC1 drives ribosome biogenesis and translation via S6K and 4E-BP1. Chronic mTORC1 hyperactivity in aging cells increases protein synthesis beyond the capacity of chaperones and quality-control systems, producing misfolded proteins. Rapamycin reduces the protein-synthetic burden, shifting the balance toward protein quality over quantity and reducing proteotoxic stress.
Suppression of senescence-associated inflammation. mTORC1 activity promotes the senescence-associated secretory phenotype (SASP) — the pro-inflammatory cytokine production by senescent cells that drives tissue-level aging. mTORC1 inhibition reduces SASP factor production, dampening the chronic low-grade inflammation ("inflammaging") that contributes to age-related tissue dysfunction.
Stem cell maintenance. mTORC1 hyperactivity depletes stem cell pools by driving differentiation and exhaustion. Rapamycin preserves the quiescence of hematopoietic stem cells, intestinal stem cells, and neural stem cells, maintaining tissue regenerative capacity with age.

The lifespan extension from rapamycin in mice is one of the most robust pharmacological longevity interventions known. Clinical trials of rapamycin analogs (rapalogs) for age-related conditions are underway, although chronic mTORC1 inhibition carries risks of immunosuppression, glucose intolerance (via insulin resistance from mTORC1's role in metabolic feedback), and impaired wound healing.

PI3K pathway mutations in cancer and pharmacological targeting Master

The PI3K-Akt-mTOR pathway is the most frequently altered signaling axis in human cancer. The Cancer Genome Atlas (TCGA) and subsequent pan-cancer analyses have established that PI3K-pathway alterations occur in more than 50% of solid tumors across all tissue types. The mutational landscape is dominated by three classes of lesion: activating mutations in PIK3CA, inactivating lesions in PTEN, and amplifications or mutations in Akt isoforms.

PIK3CA hotspot mutations

PIK3CA encodes the p110-alpha catalytic subunit of class IA PI3K. Two hotspot regions account for approximately 80% of PIK3CA mutations in cancer:

The helical domain (exon 9): E542K and E545K. These mutations disrupt the inhibitory interaction between p85 and p110, causing constitutive lipid kinase activity independent of growth-factor input. The glutamate-to-lysine substitution introduces a positive charge that mimics the charge reversal normally induced by phospho-tyrosine binding to the p85 SH2 domain.
The kinase domain (exon 20): H1047R. This mutation increases the catalytic rate of p110-alpha and alters its interaction with the membrane, enhancing access to the PIP2 substrate. Structural studies show that H1047R stabilizes the active conformation of the kinase domain's activation loop.

PIK3CA mutations are driver events in breast cancer (approximately 40% of hormone-receptor-positive tumors), endometrial cancer, colorectal cancer, and cervical cancer. The mutant allele is typically heterozygous, and mutant p110-alpha shows dominant signaling over the wild-type allele, a phenomenon explained by the constitutive membrane association of the mutant protein. Alpelisib (BYL719), an alpha-isoform-selective PI3K inhibitor, was approved in 2019 for PIK3CA-mutant HR-positive, HER2-negative advanced breast cancer (in combination with fulvestrant), representing one of the first biomarker-guided PI3K-pathway therapies.

PTEN loss

PTEN loss of function occurs through diverse mechanisms: homozygous deletion, heterozygous loss with loss of heterozygosity (LOH), point mutations in the phosphatase domain, promoter methylation, and post-translational modifications (oxidation, phosphorylation, acetylation) that reduce phosphatase activity. The resulting phenotype is elevated PIP3 and constitutive Akt activation.

PTEN loss is particularly prevalent in glioblastoma (30-40%), endometrial carcinoma (up to 80% in Type I endometrioid tumors), castration-resistant prostate cancer, and melanoma. A notable feature of PTEN biology is haploinsufficiency: heterozygous PTEN loss produces a gene-dosage-dependent increase in tumor incidence in mouse models, and humans with germline PTEN mutations (Cowden syndrome) develop multiple hamartomas and have greatly elevated cancer risk despite retaining one functional allele. The dosage sensitivity arises because PIP3 levels are set by the ratio of PI3K to PTEN activity, and a 50% reduction in PTEN shifts this ratio substantially.

Feedback mechanisms and resistance

The PI3K-Akt-mTOR pathway contains multiple feedback loops that shape both normal physiology and drug resistance:

S6K-IRS1 negative feedback. Active S6K phosphorylates IRS1 on inhibitory serine residues, targeting IRS1 for degradation. This feedback limits upstream signaling through insulin/IGF-1 receptors. mTORC1 inhibitors relieve this feedback: S6K is silenced, IRS1 is stabilized, and upstream RTK signaling to PI3K is amplified, producing rebound Akt phosphorylation at Ser473. This is the major mechanism of intrinsic resistance to rapalogs and explains their primarily cytostatic effect.
mTORC2-Akt positive feedback. mTORC2 phosphorylates Akt at Ser473, and active Akt promotes mTORC2 assembly through a mechanism involving phosphorylation of mTORC2 components. This positive feedback creates a bistable switch: once Akt activity exceeds a threshold, the positive feedback locks the pathway in the active state. Inhibition of mTORC2 (or dual mTORC1/mTORC2 inhibition) disrupts this bistability.
FOXO-RTK feedback. When Akt is inhibited (pharmacologically or physiologically), FOXO transcription factors translocate to the nucleus and induce expression of RTK ligands and RTKs themselves, creating a compensatory increase in upstream signaling. This FOXO-mediated feedback is observed in cells treated with PI3K or Akt inhibitors and contributes to adaptive resistance.

Pharmacological landscape

The PI3K-Akt-mTOR drug development effort has produced four major drug classes:

Pan-PI3K inhibitors (buparlisib, pictilisib): Block all class I PI3K isoforms. Limited by on-target toxicity (hyperglycemia, rash, mood disorders from PI3K-alpha inhibition; immunosuppression from PI3K-delta inhibition).
Isoform-selective PI3K inhibitors. Alpelisib (alpha-selective, approved for breast cancer), idelalisib and duvelisib (delta-selective, approved for hematologic malignancies where PI3K-delta drives B-cell receptor signaling). Isoform selectivity improves the therapeutic window.
mTOR kinase inhibitors (TKIs) (sapanisertib, vistusertib): ATP-competitive inhibitors that target the mTOR kinase domain, blocking both mTORC1 and mTORC2. These overcome the feedback-driven Akt reactivation seen with rapalogs by preventing mTORC2-mediated Akt S473 phosphorylation.
Dual PI3K/mTOR inhibitors (dactolisib/BEZ235, voxtalisib): Target the conserved kinase domain shared by PI3K and mTOR. These achieve the broadest pathway suppression but also the greatest toxicity, limiting dose escalation.

Rapamycin and rapalogs (everolimus, temsirolimus) are allosteric inhibitors that bind FKBP12, and the rapamycin-FKBP12 complex then binds the FRB domain of mTOR, partially inhibiting mTORC1. They do not inhibit mTORC2 acutely. Rapalogs are approved for renal cell carcinoma, breast cancer (everolimus plus exemestane), and several other indications.

Resistance mechanisms

Resistance to PI3K-pathway inhibitors occurs through several mechanisms: pathway reactivation (feedback-driven RTK upregulation, PIK3CA mutation acquisition under treatment pressure), bypass signaling (activation of MAPK pathway through KRAS mutation or RTK amplification compensates for PI3K inhibition), and phenotypic adaptation (epithelial-to-mesenchymal transition, cancer stem cell enrichment). Combination strategies under clinical investigation include PI3K inhibitors plus MEK inhibitors (targeting both pathways simultaneously), PI3K inhibitors plus immune checkpoint inhibitors (exploiting the immunomodulatory effects of PI3K inhibition), and PI3K inhibitors plus hormone therapy in breast cancer (blocking the estrogen-receptor-to-PI3K crosstalk).

mTOR in aging, autophagy, and metabolic reprogramming Master

mTOR and lifespan

The discovery that rapamycin extends lifespan in mice (Harrison et al., 2009, Nature) was a landmark in geroscience. Rapamycin administered starting at 600 days of age extended median lifespan by approximately 14% in female and 9% in male UM-HET3 mice. Subsequent studies with earlier treatment initiation achieved extensions of 20-25%. The effect has been replicated in yeast, worms, flies, and multiple mouse strains, establishing mTOR as the most conserved longevity regulator across eukaryotes.

The mechanistic basis involves three processes. First, autophagy induction: mTORC1 inhibition activates ULK1 and the autophagy machinery, clearing accumulated damage. Second, reduced translation: decreased S6K and 4E-BP1 phosphorylation lowers the rate of protein synthesis, reducing proteotoxic stress and conserving resources. Third, metabolic remodeling: mTORC1 inhibition shifts cells from anabolic to catabolic metabolism, decreasing oxidative phosphorylation demand and reactive oxygen species production.

A critical question is whether the lifespan extension from rapamycin requires chronic mTORC1 inhibition or can be achieved with intermittent dosing. Intermittent rapamycin regimens (e.g., 3 days per week) extend lifespan in male mice almost as effectively as continuous treatment, suggesting that periodic autophagy induction may be sufficient. This has practical implications because chronic rapamycin causes glucose intolerance (via inhibition of the insulin-sensitizing effects of mTORC2 in liver and muscle), immunosuppression (via effects on T-cell proliferation), and impaired wound healing.

Autophagy regulation

mTORC1 is the master negative regulator of autophagy. The connection proceeds through ULK1 (UNC-51-like kinase 1), the initiator of autophagosome formation. Under nutrient-rich conditions, mTORC1 phosphorylates ULK1 on Ser757, disrupting the ULK1-AMPK interaction and keeping ULK1 inactive. Under starvation or rapamycin treatment, mTORC1 is inactive, ULK1 is dephosphorylated at Ser757, AMPK phosphorylates ULK1 on activating sites (Ser317, Ser777), and ULK1 initiates the autophagy cascade.

The autophagy program proceeds through: (1) ULK1 complex activation (ULK1-ATG13-FIP200-ATG101), (2) PI3K-III complex recruitment (VPS34-Beclin1-ATG14L) generating PI(3)P on nascent autophagosomal membranes, (3) ATG5-ATG12-ATG16L1 conjugation and LC3-II lipidation expanding the membrane, and (4) selective cargo recognition by autophagy receptors (p62/SQSTM1, NBR1, OPTN) that link ubiquitinated cargo to LC3-II on the autophagosome.

mTORC1 also regulates autophagy at the transcriptional level through TFEB (transcription factor EB), the master regulator of lysosomal and autophagy gene expression. Under nutrient-rich conditions, mTORC1 phosphorylates TFEB on Ser211, promoting 14-3-3 binding and cytoplasmic sequestration. When mTORC1 is inactive, TFEB is dephosphorylated, translocates to the nucleus, and activates a network of genes encoding lysosomal hydrolases, autophagy machinery components, and lysosomal biogenesis factors.

mTORC2 in cytoskeletal organization and metabolism

mTORC2 has distinct substrates from mTORC1 and controls different cellular processes. The best-characterized mTORC2 substrates are:

Akt (Ser473): As discussed above, mTORC2-mediated Ser473 phosphorylation is required for full Akt activity. mTORC2 also phosphorylates Akt on Thr450 in the turn motif, which stabilizes the Akt protein.
SGK1 (serum/glucocorticoid-regulated kinase 1): mTORC2 phosphorylates SGK1 on its hydrophobic motif, activating this kinase that controls ion transport in the kidney. SGK1 regulates the epithelial sodium channel (ENaC), and mTORC2 inhibition produces the hyperglycemia observed with rapamycin treatment through effects on hepatic gluconeogenesis and insulin resistance.
PKC-alpha: mTORC2 phosphorylates conventional and novel PKC isoforms on their hydrophobic motifs, controlling their stability and activity. PKC-alpha regulates cytoskeletal organization, cell migration, and cell adhesion through effects on Rho GTPases and the actin cytoskeleton.

mTORC2 is activated by growth factors through a mechanism that involves PI3K-produced PIP3 (creating a positive feedback loop: PI3K activates Akt, which promotes mTORC2 assembly, which further activates Akt). Ribosomes have also been proposed as a platform for mTORC2 activation, linking mTORC2 to the translational capacity of the cell.

Metabolic reprogramming by the PI3K-Akt-mTOR axis

The PI3K-Akt-mTOR pathway controls cellular metabolism at multiple nodes, and its dysregulation in cancer produces the metabolic reprogramming known as the Warburg effect (aerobic glycolysis) and related phenotypes:

Glucose uptake and glycolysis. Akt promotes GLUT4 translocation to the plasma membrane (increasing glucose uptake), activates hexokinase 2 (trapping glucose intracellularly as glucose-6-phosphate), and phosphorylates PFKFB3 (increasing fructose-2,6-bisphosphate, a potent allosteric activator of phosphofructokinase-1). mTORC1 drives HIF1-alpha translation, further increasing glycolytic enzyme expression.
Lipid synthesis. mTORC1 activates SREBP1 (sterol regulatory element-binding protein 1), the master transcription factor for lipogenic genes (fatty acid synthase, acetyl-CoA carboxylase, HMG-CoA reductase). PI3K-Akt signaling also activates SREBP1 processing through mTORC1-independent mechanisms involving the SCAP-Insig pathway.
Nucleotide synthesis. mTORC1 stimulates de novo pyrimidine synthesis through phosphorylation and activation of CAD (carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase), the rate-limiting enzyme of pyrimidine biosynthesis. Purine synthesis is enhanced through mTORC1-mediated activation of the pentose phosphate pathway and one-carbon metabolism.
Glutamine metabolism. mTORC1 stimulates glutaminolysis through SLC1A5 (glutamine transporter) expression and glutaminase activation, providing alpha-ketoglutarate to replenish the TCA cycle (anaplerosis) in rapidly dividing cells.

The integrated metabolic program driven by PI3K-Akt-mTOR is the molecular basis of the cancer metabolic phenotype: high glucose consumption, lactate production despite oxygen availability, enhanced lipid and nucleotide synthesis, and glutamine addiction.

Connections Master

Cell signaling: receptors and GPCRs 17.07.01. The PI3K-Akt-mTOR pathway receives inputs from GPCRs as well as RTKs. G-beta-gamma subunits from Gi-coupled receptors activate PI3K-gamma (class IB). Gq-mediated PKC activation stimulates class IA PI3Ks. The convergence of GPCR and RTK inputs on PI3K creates coincidence detection at the cellular level.
RTK-MAPK signaling cascade 17.07.02. Ras-GTP activates both the MAPK cascade (through Raf) and PI3K (through the p110 Ras-binding domain). The two pathways share upstream inputs (RTKs, Ras) and exhibit crosstalk at multiple levels: ERK phosphorylates TSC2 (activating it, opposing Akt), and S6K phosphorylates IRS1 (negative feedback that also dampens MAPK input). In cancer, the two pathways provide redundant proliferative signals, and combined inhibition of both MAPK and PI3K is often required for therapeutic effect.
Cell cycle and mitosis 17.08.01. Akt drives G1/S progression by phosphorylating and excluding FOXO transcription factors (reducing p27 and p21 expression), stabilizing cyclin D1 (via GSK3-beta inhibition), and activating mTORC1 (increasing the translational capacity needed for cell division). The PI3K pathway is a major input to the cell-cycle decision machinery.
Cellular respiration 17.04.01. mTORC1 controls the switch between glycolysis and oxidative phosphorylation through HIF1-alpha translation, SREBP activation, and mitochondrial biogenesis regulation via PGC-1alpha. The Warburg effect in cancer is driven in part by PI3K-Akt-mTOR hyperactivation.
Lipid chemistry 17.01.04 pending. The PI3K reaction (PIP2 to PIP3) is a lipid phosphorylation event on the inositol ring of a phosphoinositide. Understanding the pathway requires familiarity with the structure and membrane topology of phosphatidylinositol and its phosphorylated derivatives.
Cytoskeleton 17.03.02. mTORC2 controls actin dynamics through PKC-alpha and Rho GTPase signaling. Cell migration and invasion in metastatic cancer are influenced by mTORC2-dependent cytoskeletal reorganization.
Protein structure 17.01.02 pending. The PH domain of Akt, the SH2 domains of p85, the kinase domain of p110, and the FAT domain of mTOR are all structurally characterized. The allosteric inhibition of p110 by p85, and its relief by phospho-tyrosine binding, are understood at atomic resolution from crystal structures of the p85-p110 complex.

Historical notes Master

The PI3K pathway was discovered in the late 1980s through two independent lines of investigation. Lewis Cantley and colleagues identified a phosphoinositide kinase activity associated with polyoma middle T antigen and src that phosphorylated the 3-position of the inositol ring, distinct from the known 4- and 5-kinases. This activity, initially called PI3-kinase, was subsequently purified and shown to be a heterodimer of p85 and p110 subunits. The link to oncogenesis came when PI3K activity was found to be associated with activated RTKs and to be stimulated by Ras.

PTEN was identified independently by three groups in 1997 as a tumor suppressor gene on chromosome 10q23 that is frequently deleted in glioblastoma and other cancers. The recognition that PTEN is a lipid phosphatase that dephosphorylates PIP3 was made by Maehama and Dixon in 1998, establishing PTEN as the direct antagonist of PI3K and explaining its tumor-suppressor function at the molecular level.

mTOR was discovered through the mechanism of action of rapamycin, an antifungal macrolide produced by Streptomyces hygroscopicus, originally isolated from a soil sample on Easter Island (Rapa Nui) in 1972. Rapamycin was initially developed as an immunosuppressant and anti-cancer agent. The identification of the FKBP12-rapamycin binding (FRB) domain and the cloning of the mTOR gene (originally called FRAP, RAFT1, or SEP in different organisms) were achieved in 1994-1995. The recognition that mTOR exists in two distinct complexes — mTORC1 (Raptor-containing, rapamycin-sensitive) and mTORC2 (Rictor-containing, rapamycin-insensitive) — came from the laboratories of David Sabatini and Michael Hall in 2004.

The amino-acid-sensing pathway was elucidated over the following decade. The Rag GTPases were identified as amino-acid-dependent regulators of mTORC1 localization by the Sabatini laboratory in 2008. The Ragulator complex, the v-ATPase-Ragulator interaction, and the GATOR1/GATOR2 regulators were characterized between 2010 and 2015, establishing the lysosome as the signaling hub for nutrient sensing. The identification of Sestrin2 as the leucine sensor and CASTOR1 as the arginine sensor completed the amino-acid-sensing module.

The Saxton and Sabatini 2017 Cell review synthesized two decades of mTOR research into a coherent framework, presenting mTORC1 as a multi-input integrator whose output controls the balance between anabolism and catabolism. The Fruman et al. 2017 Cell review provided the disease-focused complement, cataloguing PI3K-pathway alterations across cancers and the pharmacological landscape of PI3K/mTOR inhibitors.

Bibliography Master

Alberts, B. et al., Molecular Biology of the Cell, 7th ed., Garland Science (2022), Ch. 15 Cell Signaling.
Lodish, H. et al., Molecular Cell Biology, 9th ed., W. H. Freeman (2021), Ch. 16 Cell Signaling.
Saxton, R. A., Sabatini, D. M., "mTOR signaling in growth, metabolism, and disease", Cell 168 (2017), 960-976.
Fruman, D. A. et al., "The PI3K pathway in human disease", Cell 170 (2017), 605-635.
Cantley, L. C., "The phosphoinositide 3-kinase pathway", Science 296 (2002), 1655-1657.
Maehama, T., Dixon, J. E., "The tumor suppressor, PTEN, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate", J. Biol. Chem. 273 (1998), 13375-13378.
Harrison, D. E. et al., "Rapamycin fed late in life extends lifespan in genetically heterogeneous mice", Nature 460 (2009), 689-692.
Sancak, Y. et al., "The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1", Science 320 (2008), 1496-1501.
Sabatini, D. M., "Twenty-five years of mTOR: uncovering the link from nutrients to growth", Proc. Natl. Acad. Sci. USA 114 (2017), 11818-11825.
Manning, B. D., Toker, A., "AKT/PKB signaling: navigating the network", Cell 169 (2017), 381-405.
Laplante, M., Sabatini, D. M., "mTOR signaling in growth control and disease", Cell 149 (2012), 274-293.
Dibble, C. C., Cantley, L. C., "Regulation of mTORC1 by PI3K signaling", Trends Cell Biol. 25 (2015), 545-555.
Andre, F. et al., "Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer", New Engl. J. Med. 380 (2019), 1929-1940.

Status: stub. Pending Tyler review and external biology reviewer.